Only 30% of People Stay on GLP-1s Past a Year. That Is Why Microdosing Exploded.

Here is the number that explains the whole trend. A study of 201,229 American adults who started GLP-1 drugs for obesity, published in Diabetes, Obesity and Metabolism in September 2026, sorted them into twelve-month adherence trajectories. Just 30.7% were persistent users. Nearly one in five filled a prescription and stopped almost immediately. Add the early and late discontinuers and roughly two thirds of everyone who starts a GLP-1 drug is off it within a year.

The industry's answer to that problem has been to sell more drug. The internet's answer has been to take less of it.

Microdosing GLP-1 drugs — using a fraction of the manufacturer's recommended dose, or stretching the interval between injections — has moved from scattered forum posts to its own subreddit, its own telehealth niche, and its own peer-reviewed commentary. Three papers tried to make sense of it in 2026. The practice is running well ahead of the evidence, and the reasons people turn to it are more rational than the practice itself.

What 'microdosing' actually means

There is no official definition. The closest thing to one comes from a September 2026 commentary in Expert Opinion on Pharmacotherapy by Beck and Clements of the University of South Carolina College of Pharmacy, which describes microdosing as using 25 to 50 percent of the recommended starting dose, or extending the dosing interval beyond the standard weekly schedule. Techniques vary: some patients dial a multi-dose pen partway — the community calls it click counting, because the pen clicks as you turn the dial — while others use compounded vials and insulin syringes to measure fractions of a starting dose.

The drivers are not mysterious. GLP-1 side effects are dose-dependent, mostly gastrointestinal, and worst during dose escalation. Cost and access barriers are documented in every review of real-world GLP-1 use: a September 2026 narrative review in Diabetes, Obesity and Metabolism found that real-world weight loss trails trial results largely because of non-initiation, incomplete dose escalation, gastrointestinal intolerance, treatment interruptions, and price. Microdosing is what happens when patients decide to solve the tolerability and cost problem themselves.

A note on what microdosing is not. The word borrows credibility from microdosing in drug development, where sub-pharmacologic doses are used in early safety studies. That is a formal research practice with measured plasma levels. Self-directed microdosing of a peptide injection is a different thing entirely, and the borrowed vocabulary flatters it.

What the 2026 literature actually says

Start with the honest summary from Beck and Clements: high-quality clinical evidence is essentially absent. Their commentary reports early signals — reduced nausea, better adherence, modest weight loss in some users — drawn from real-world reports and clinician anecdotes, not trials.

The July 2026 Cureus narrative review by Panlilio and colleagues goes further, framing long-term microdosing as offering multisystem benefits. Read its references before you quote the title. The supporting evidence is extrapolated almost entirely from studies of standard-dose GLP-1 drugs and other agents altogether. Nothing in it establishes that a quarter dose delivers a quarter of the benefit, or a half, or anything at all. The plausible inference — lower dose, fewer side effects, some effect — is reasonable as a hypothesis. It is not a finding.

The third paper, a May 2026 brief report in the Journal of the American Association of Nurse Practitioners by Trainer, is the most useful for anyone actually doing this. It catalogues what goes wrong: pen manipulation, dose measurement errors, medication sharing, and the safety problems of compounded vials. It also names a driver that does not get enough attention — provider weight bias pushing patients toward unsupervised alternatives in the first place.

The pharmacology question nobody has tested

GLP-1 receptor agonists have a real dose-response relationship for both effect and side effects. At standard maintenance doses, semaglutide produces roughly 15% weight loss and tirzepatide up to 20% or more in trials, with nausea rates that climb during escalation. Starting doses exist for a reason: they are sub-therapeutic for weight loss and meant to be transient. The one piece of genuine low-dose data in obesity is a Japanese study finding 2.5 mg tirzepatide performed similarly to 5 mg in non-diabetic adults — a finding Oria covered when it published — but 2.5 mg is a labeled dose, not a microdose.

So the microdosing claim sits on an untested assumption: that the dose-response curve is kind to small doses. For appetite and gastric emptying, partial receptor engagement is biologically plausible and probably does something. How much, for how long, at what cost to lean mass and metabolic rate during slower weight loss — nobody has measured. There is no registered trial testing a microdosing regimen for obesity that I could find in the published literature. If the practice works, it works on anecdote. If it fails quietly, nobody will know.

The safety ledger is not empty

While efficacy data is thin, the risk data is unusually concrete. A pharmacovigilance study by McCall and colleagues, published in Expert Opinion on Drug Safety in March 2026, pulled every GLP-1 report in the FDA's adverse event database from 2018 to 2024. Of 81,078 reports, 707 involved compounded products — and those skewed sharply toward problems. Preparation errors were reported roughly 49 times more often than with approved products. Contamination reports ran about 19 times higher. Hospitalization was about twice as likely to be reported.

That is not a microdosing study. It is a study of the supply chain that a large share of microdosing runs on. When a patient measures a fractional dose from a compounded vial with an insulin syringe, two unvalidated steps stack: the product's actual concentration and the patient's measurement of it. Community posts illustrate the second problem plainly. One r/GLP1microdosing thread walks a newcomer through how many units of a vial equal 0.2 mg. Another user on r/cfs reports being told that Mounjaro pens in their country cannot be click-counted at all. Dose accuracy is device-specific, product-specific, and entirely unregulated in practice.

The legal backdrop matters too. Compounded semaglutide and tirzepatide were lawful only while the drugs sat on the FDA shortage list. The FDA resolved the tirzepatide shortage on December 19, 2024 and the semaglutide shortage on February 21, 2025, with wind-down deadlines for compounders running through May 2025 and more than 50 warning letters issued that September. In April 2026 the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list outright. Microdosing itself is not illegal — using a prescribed approved drug at a lower dose is between a patient and their prescriber. The market that grew around it has been steadily closing.

What users report

Community reports are consistent on the appeal and chaotic on the execution. On r/GLP1microdosing, one user starting semaglutide describes click counting a Wegovy kwickpen to deliver 0.05 mg — seven clicks instead of a full 0.25 mg dose — and pointing to community-written dosing guides. The thread titles on the subreddit tell their own story: dosing math questions, confusion after a first delivery arrives, and a recurring one about whether to go through a doctor or an online service. These are self-selected accounts from people motivated to make the practice work. They are useful as evidence of what the practice looks like on the ground, and nothing more.

The Oria take

The instinct behind microdosing is defensible. Roughly two thirds of patients cannot or will not stay on standard-dose GLP-1 therapy at full escalation, and the medical system's answer to that is mostly to push through it. A well-tested, precisely dosed low-dose regimen would genuinely help people. That regimen does not exist yet. What exists is self-experimentation layered on a supply chain with a documented error problem, dressed in vocabulary that sounds more scientific than it is.

If you are researching this space, three things are worth carrying forward. Dose-response for GLP-1 weight loss at sub-starting doses is unmeasured, so expectations should be humble. Product provenance matters more at fractional doses, because absolute errors grow relative to the intended dose. And the most defensible version of this conversation happens with a prescriber who will document a plan, follow your response, and treat the dose as a clinical variable rather than a hack.

Evidence grade: D — no randomised trial has tested a microdosing regimen for weight loss. The pharmacologic rationale is plausible, the community evidence is self-reported and self-selected, and the safety data on compounded products is the strongest evidence in the set — and it points the wrong way.

Sources

Huang W, et al. Real-World Adherence Trajectories of GLP-1 Receptor Agonists Among Adults and Paediatric Patients With Obesity. Diabetes Obes Metab. 2026 Sep 17. PMID 42755139.

Beck H, Clements JN. Considerations and challenges in microdosing of GLP-1-based receptor agonists. Expert Opin Pharmacother. 2026 Sep 25. PMID 42788826.

Panlilio MA, et al. Multisystem Benefits of GLP-1 Microdosing: A Narrative Review. Cureus. 2026 Jul 30;18(7):e113635. PMID 42668762.

Trainer N. The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. J Am Assoc Nurse Pract. 2026 May 26. PMID 42201545.

McCall KL, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opin Drug Saf. 2026 Mar;25(3):581-588. PMID 40285721.

Kassem S. Real-World Evidence for Existing Anti-Obesity Therapies — The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction. Diabetes Obes Metab. 2026 Sep;28 Suppl 5:3-26. PMID 42736522.

Community reports: r/GLP1microdosing (reddit.com/r/GLP1microdosing) and r/cfs, accessed October 2026.

FDA shortage determinations for tirzepatide (December 19, 2024) and semaglutide (February 21, 2025); 503B bulks list proposal (April 30, 2026).

Medical disclaimer

Oria publishes research summaries, not medical advice. Nothing here is a recommendation to start, stop, or alter any medication, and GLP-1 receptor agonists are prescription drugs whose dosing should be managed by a licensed clinician. This article reports published research and community accounts as of October 2026; evidence in this area is evolving quickly. Oria exists because the space between hype and evidence is where people get hurt — we write for that gap.